May 12, 2022
Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute
May 10, 2022
Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates
May 04, 2022
Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference
May 02, 2022
Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting
Mar 16, 2022
Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
Mar 09, 2022
Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference
Mar 08, 2022
Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting
Jan 11, 2022
Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct
Jan 10, 2022
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
Jan 04, 2022
Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference